INNOVENT BIO (01801.HK) +1.950 (+2.189%) Short selling $58.19M; Ratio 18.616% opened nearly 4.7% higher this morning, and swelled 5.9% to $84.2 in the morning session. Trading volume was 3.895 million shares, involving $330 million. The Company entered into a global strategic collaboration with Eli Lilly and Company (LLY.US) to advance novel medicines in oncology and immunology.INNOVENT BIO, drawing on its robust antibody technology platforms and efficient clinical execution, will lead the development of programs from concept through clinical proof-of-concept (Phase 2 clinical trial completion) in China. Related NewsUOB Kay Hian Favors ALI HEALTH, PA GOODDOCTOR; AI Innovation & National Policies Drive CN Internet Healthcare SectorThe agreement grants Eli Lilly an exclusive worldwide license to develop and commercialize the programs worldwide outside Greater China. Meanwhile, INNOVENT BIO will receive a US$350 million upfront payment and is eligible to receive development, regulatory and commercial milestone payments totaling up to approx. US$8.5 billion contingent upon the achievement of certain future events.(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-02-16 12:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)